News | Postbiotics may offer a new direction for PCOS treatment: regulating the gut microbiota may improve metabolic and hormonal imbalances
Growing evidence suggests that the gut microbiota may play an important role in the onset and progression of polycystic ovary syndrome (PCOS). A recent review published in ACS Nutrition Science noted that postbiotics—bioactive substances produced by microorganisms—may offer a new adjunctive strategy for PCOS treatment by restoring balance in the gut microbiome.
Researchers believe these microbial metabolites may not only improve insulin resistance but also affect inflammation and hormone levels, potentially influencing multiple PCOS symptoms.
PCOS is a complex endocrine and metabolic disorder
Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age. It typically involves elevated androgen levels, ovulatory dysfunction, and polycystic ovarian morphology.
People with PCOS often have metabolic abnormalities and symptoms such as insulin resistance, weight gain, acne, excess hair growth, and infertility. The condition is thought to result from a combination of genetic and environmental factors.
In recent years, scientists have begun examining the potential role of the gut microbiota in PCOS and have found growing evidence of an important association.
Gut dysbiosis may contribute to PCOS
The human gut contains extensive microbial communities, including beneficial bacteria such as Bifidobacterium and Lactobacillus, as well as potential pathogens such as Staphylococcus aureus and Clostridium difficile.
When the balance between beneficial and potentially harmful bacteria is disrupted, this is known as gut dysbiosis.
Studies show that people with PCOS often have this microbial imbalance, including:
Fewer beneficial bacteria
A higher proportion of potential pathogens
Reduced microbial diversity
Some studies have also observed increases in certain bacterial groups, such as Actinobacteria, and species such as Escherichia coli.
These microbial changes may be associated with the metabolic dysfunction, inflammation, and impaired intestinal barrier function commonly seen in PCOS.
Postbiotics: active substances produced by microorganisms
As microbiome research advances, scientists are increasingly focusing on the concept of postbiotics.
Postbiotics generally refer to bioactive substances or cellular components produced by microorganisms or derived from microbial metabolism, such as:
Short-chain fatty acids (SCFAs)
Certain vitamins
Enzymes
Cell-surface structural components
Unlike probiotics, postbiotics do not contain live microorganisms, giving them certain advantages in storage stability.
Preliminary studies suggest that these substances may have several biological effects, including improving insulin sensitivity, reducing inflammation, and regulating gut microbiota composition.
Short-chain fatty acids may play a key role in PCOS
Among postbiotics, short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are considered physiologically important.
These molecules are an important energy source for intestinal epithelial cells and also have anti-inflammatory and immune-regulating effects.
Gut dysbiosis may reduce SCFA production, impairing the intestinal barrier and allowing bacterial toxins to enter the bloodstream more easily and trigger inflammation.
Researchers believe this process may explain why some people with PCOS have higher blood levels of endotoxins from gram-negative bacteria.
SCFAs are also involved in appetite regulation, fat metabolism, and glucose metabolism, and may improve insulin sensitivity.
Because insulin resistance is a major pathological feature of PCOS, these effects may have potential relevance for disease management.
The gut microbiota may also affect hormone levels
Beyond its metabolic effects, the gut microbiota also participates in estrogen metabolism.
Changes in gut microbiota composition may affect active estrogen levels in the body, further worsening the hormonal imbalance commonly seen in PCOS.
At the same time, insulin resistance may lower sex hormone-binding globulin (SHBG) levels and promote androgen production, contributing to hyperandrogenism and menstrual irregularities in PCOS.
A potential complement to existing treatments
Current PCOS treatment generally combines strategies such as lifestyle changes, medication, and nutritional supplements.
Common treatments include:
Exercise and dietary management
Metformin to improve insulin sensitivity
Oral contraceptives to regulate menstrual cycles
Antiandrogen medications, such as spironolactone, to reduce excess hair growth or acne
The review suggests that postbiotics could complement these treatments in the future.
For example, by increasing SCFA levels, postbiotics may improve insulin sensitivity and reduce inflammation. They may also affect bile acid metabolism and glucose and lipid metabolism, improving metabolic health.
Some postbiotic components, such as exopolysaccharides, have also shown potential antioxidant and lipid-regulating effects in experimental studies, which may be particularly relevant to people with obesity-related PCOS.
More clinical research is needed
Despite interest in this promising research area, scientists note that evidence for using postbiotics to treat PCOS remains limited.
Existing studies face several issues. The definition of postbiotics is not yet fully standardized, and studies vary widely in strain selection and preparation methods, creating challenges for regulation and comparison of results.
Many studies also remain at the mechanistic or animal-experiment stage, with relatively few clinical studies involving women with PCOS.
Researchers emphasize the need for long-term, systematic human studies to establish the safety, effectiveness, and optimal use of postbiotics in PCOS management.
Nevertheless, as gut microbiome research advances, microbiota-based strategies may play an increasingly important role in personalized PCOS treatment.
News | Postbiotics May Offer a New Direction for PCOS Treatment by Modulating Gut Microbiota and Improving Metabolic and Hormonal Imbalances
News | Postbiotics may offer a new direction for PCOS treatment: regulating the gut microbiota may improve metabolic and hormonal imbalances
Growing evidence suggests that the gut microbiota may play an important role in the onset and progression of polycystic ovary syndrome (PCOS). A recent review published in ACS Nutrition Science noted that postbiotics—bioactive substances produced by microorganisms—may offer a new adjunctive strategy for PCOS treatment by restoring balance in the gut microbiome.
Researchers believe these microbial metabolites may not only improve insulin resistance but also affect inflammation and hormone levels, potentially influencing multiple PCOS symptoms.
PCOS is a complex endocrine and metabolic disorder
Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age. It typically involves elevated androgen levels, ovulatory dysfunction, and polycystic ovarian morphology.
People with PCOS often have metabolic abnormalities and symptoms such as insulin resistance, weight gain, acne, excess hair growth, and infertility. The condition is thought to result from a combination of genetic and environmental factors.
In recent years, scientists have begun examining the potential role of the gut microbiota in PCOS and have found growing evidence of an important association.
Gut dysbiosis may contribute to PCOS
The human gut contains extensive microbial communities, including beneficial bacteria such as Bifidobacterium and Lactobacillus, as well as potential pathogens such as Staphylococcus aureus and Clostridium difficile.
When the balance between beneficial and potentially harmful bacteria is disrupted, this is known as gut dysbiosis.
Studies show that people with PCOS often have this microbial imbalance, including:
Fewer beneficial bacteria
A higher proportion of potential pathogens
Reduced microbial diversity
Some studies have also observed increases in certain bacterial groups, such as Actinobacteria, and species such as Escherichia coli.
These microbial changes may be associated with the metabolic dysfunction, inflammation, and impaired intestinal barrier function commonly seen in PCOS.
Postbiotics: active substances produced by microorganisms
As microbiome research advances, scientists are increasingly focusing on the concept of postbiotics.
Postbiotics generally refer to bioactive substances or cellular components produced by microorganisms or derived from microbial metabolism, such as:
Short-chain fatty acids (SCFAs)
Certain vitamins
Enzymes
Cell-surface structural components
Unlike probiotics, postbiotics do not contain live microorganisms, giving them certain advantages in storage stability.
Preliminary studies suggest that these substances may have several biological effects, including improving insulin sensitivity, reducing inflammation, and regulating gut microbiota composition.
Short-chain fatty acids may play a key role in PCOS
Among postbiotics, short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are considered physiologically important.
These molecules are an important energy source for intestinal epithelial cells and also have anti-inflammatory and immune-regulating effects.
Gut dysbiosis may reduce SCFA production, impairing the intestinal barrier and allowing bacterial toxins to enter the bloodstream more easily and trigger inflammation.
Researchers believe this process may explain why some people with PCOS have higher blood levels of endotoxins from gram-negative bacteria.
SCFAs are also involved in appetite regulation, fat metabolism, and glucose metabolism, and may improve insulin sensitivity.
Because insulin resistance is a major pathological feature of PCOS, these effects may have potential relevance for disease management.
The gut microbiota may also affect hormone levels
Beyond its metabolic effects, the gut microbiota also participates in estrogen metabolism.
Changes in gut microbiota composition may affect active estrogen levels in the body, further worsening the hormonal imbalance commonly seen in PCOS.
At the same time, insulin resistance may lower sex hormone-binding globulin (SHBG) levels and promote androgen production, contributing to hyperandrogenism and menstrual irregularities in PCOS.
A potential complement to existing treatments
Current PCOS treatment generally combines strategies such as lifestyle changes, medication, and nutritional supplements.
Common treatments include:
Exercise and dietary management
Metformin to improve insulin sensitivity
Oral contraceptives to regulate menstrual cycles
Antiandrogen medications, such as spironolactone, to reduce excess hair growth or acne
The review suggests that postbiotics could complement these treatments in the future.
For example, by increasing SCFA levels, postbiotics may improve insulin sensitivity and reduce inflammation. They may also affect bile acid metabolism and glucose and lipid metabolism, improving metabolic health.
Some postbiotic components, such as exopolysaccharides, have also shown potential antioxidant and lipid-regulating effects in experimental studies, which may be particularly relevant to people with obesity-related PCOS.
More clinical research is needed
Despite interest in this promising research area, scientists note that evidence for using postbiotics to treat PCOS remains limited.
Existing studies face several issues. The definition of postbiotics is not yet fully standardized, and studies vary widely in strain selection and preparation methods, creating challenges for regulation and comparison of results.
Many studies also remain at the mechanistic or animal-experiment stage, with relatively few clinical studies involving women with PCOS.
Researchers emphasize the need for long-term, systematic human studies to establish the safety, effectiveness, and optimal use of postbiotics in PCOS management.
Nevertheless, as gut microbiome research advances, microbiota-based strategies may play an increasingly important role in personalized PCOS treatment.
Story source:
Collected online